Neuroone Medical Technology Corp.’s thin film, high definition cortical electrode technology, Evo, can record, monitor, ablate, and stimulate brain tissue for up to 30 days, potentially transforming neurosurgical procedures used to treat epilepsy, Parkinson’s disease, chronic pain, and other conditions.

PERTH, Australia – With 1 in 3 patients with type 2 diabetes likely to develop diabetic kidney disease (DKD), Perth-based Proteomics International Laboratories Ltd. has developed a blood-based diagnostic test that can predict the onset of DKD, enabling patients to get treatment sooner to prevent the onset of the disease.

Clearcam Inc.'s Kelling device has an improved view of the market thanks to the closing of a $2.6 million series 2 seed financing round, led by investor and entrepreneur Frank Barbella, CEO of Solv Risk Solutions.

CAPS Medical, of Netanya, Israel, closed a $3.5 million series A round led by Chasing Value Asset Management and the Los Angeles-based Israel Investment Fund Group. The new funds will be used to enable CAPS to undertake its first clinical trial for its minimally invasive, nonthermal plasma device for cancer treatment and further develop its portfolio for the treatment of solid tumors.

PERTH, Australia – Startup Inventia Life Science Pty. Ltd. has received two major investments from the Australian government to accelerate the development of a robotic device that prints a patient’s own skin cells directly onto a burn or wound. Named Ligō from the Latin “to bind,” the device could revolutionize the way surgeons approach wound repair.

Endpoint Health Inc. has made its official debut, scooping up $12 million in debt and equity financing from a host of investors, including Mayfield, Y Combinator, Ame Cloud Ventures and Wireframe Ventures. The Palo Alto, Calif.-based company is focused on helping people with illnesses such as sepsis and acute respiratory distress syndrome (ARDS) – life-threatening conditions often caused by serious infections, including COVID-19.

Mastor SAS secured €3 million (US$3.39 million) in seed investment from Sofinnova Partners' MD Start III Fund and €1.9 million in non-dilutive funding through the i-Nov Innovation Award from BPI France, the French national public investment bank.

Protaryx Medical has picked up $8.3 million to develop its device for precision transseptal access to the left atrium for use during structural heart and catheter ablation procedures. The funding includes nondilutive grants and a seed round totaling $3.2 million, as well as the recently closed $5.1 million series A financing led by Ajax Health, with participation from returning investor University of Maryland (UM) Ventures.

TORONTO – Once he’d enrolled in an entrepreneurial engineering course, third-year medical school student Gabriel Georges’ task was deceptively simple: come up with a device to meet an unmet medical need. Before long, Georges had pulled two other students with engineering and investor relations smarts into the project, developing a minimally invasive, long-term transcatheter heart pump that this month garnered financing from Canadian and U.S. investors.